Biotech / Medical
BTX BioTime
An SI Board Since July 2014
Posts SubjectMarks Bans Symbol
68 7 0 BTX
Emcee:  Savant Type:  Moderated
BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime's focus is on pluripotent stem cell technology based on human embryonic stem ("hES") cells and induced pluripotent stem ("iPS") cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime's therapeutic and research products include a wide array of proprietary PureStem(R) progenitors, HyStem(R) hydrogels, culture media, and differentiation kits. BioTime is developing Renevia(TM) (a HyStem(R) product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, and is planning to initiate a pivotal clinical trial around Renevia(TM), in 2014. In addition, BioTime has developed Hextend(R) , a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend(R) is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
68RT AST> sterias Biotherapeutics to Discuss Cancer Immunotherapy ProductSavant-May 17
67 RT--Asterias/they might want to do a study of salamander radial glial stem cellSavant-11/2/2017
66Asterias Announces Two Significant Developments for Spinal Cord Injury ProgSavant-10/2/2017
65Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VASavant-9/26/2017
64Asterias' AST-OPC1 Clinical Trial Will Continue as Planned Following ReSavant-9/25/2017
63 ALAMEDA, Calif.--(BUSINESS WIRE)--September 14, 2017-- BioTime, Inc. (NYSE AmeSavant-9/14/2017
62BioTime Inc. (BTX) filed a Form 8K - Changes to Articles of Incorporation or BylSavant-9/14/2017
61 FREMONT, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, ISavant-9/6/2017
60Asterias Biotherapeutics Reports Second Quarter Financial Results and Reviews ReSavant-8/16/2017
59AST Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial Savant-8/9/2017
58AST Former Quadriplegic Enrolled in Asterias' SCiStar Study to Throw CeremoSavant-8/8/2017
57Asterias Biotherapeutics Opens Two Additional Clinical Sites for AST-OPC1 SCiStaSavant-8/3/2017
56 AST ... Ability to enroll patients with second most common cervical spinal corSavant-7/10/2017
55 Presentation by AST today 9 mon. results slides @ link Third patient recovers Savant-6/13/2017
54Further great news for spinal injury patients.. Update on Full Six-Patient CohSavant-3/21/2017
53 BTX & OCX BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte SSavant-2/22/2017
52BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company deSavant-2/15/2017
51 BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Savant-2/6/2017
50AST - AST.WS Asterias Biotherapeutics Extends the Expiration Date of Certain WSavant-2/3/2017
49 BioTime to Present at Noble Capital Markets Thirteenth Annual Investor ConferenSavant-1/26/2017
48Additional Data From BioTimes OpRegen(R) Clinical Trial in Dry-AMD to be PresentSavant-1/19/2017
47 Asterias Announces Successful Commencement of Operations at New GMP ManufacturiSavant-1/9/2017
46 BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell TheraSavant-1/3/2017
45 Ascendance Biotechnology Licenses the Right to Manufacture, Market and Sell CytSavant-12/28/2016
44BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial Dec 14,Savant-12/14/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.